NZ189159A - Oral antihypertensive compositions containing proline derivatives - Google Patents
Oral antihypertensive compositions containing proline derivativesInfo
- Publication number
- NZ189159A NZ189159A NZ189159A NZ18915978A NZ189159A NZ 189159 A NZ189159 A NZ 189159A NZ 189159 A NZ189159 A NZ 189159A NZ 18915978 A NZ18915978 A NZ 18915978A NZ 189159 A NZ189159 A NZ 189159A
- Authority
- NZ
- New Zealand
- Prior art keywords
- hydrogen
- dosage unit
- carbon atoms
- lower alkyl
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Description
New Zealand Paient Spedficaiion for Paient Number 1 89159
1891
Priority C-COiTfcpteiii
r::7:'.cztiavi Filed: !?;7$
l*P..£,
DEC 1984
r.,.
j I 4 B 9 ® ® ® ®
NEW ZEALAND £ PATENT Orf-ICE
PATENTS ACT, 1953
J 3 DEC 1978
no, r BECBVgg^
Date:
COMPLETE SPECIFICATION "METHOD OF TREATING HYPERTENSION AND MEDICAMENTS THEREFOR"
i/We, E. R. SQUIBB & SONS, INC. a corporation of Delaware of Lawrenceville-Princeton Road, Princeton, New Jersey 08540, United States of America .
hereby declare the invention for which / we pray that a patent may be granted to ccsc/us, and the method by which it is to be performed, to be particularly described in and by the following statement: -
followed by page la
189159
*HAl60a-
Method of Tr eg Liny Hyyfcti tanslart arrd-
i ^pmonfc Tb^TPfnr
The present invention relates to a method for reducing or alleviating hypertension with a combination 10 comprising an effective amount of a compound of the formula (I)
P. & S-
R4 R1 _/R3
R„-S- (CH) — CH- CO - N. 2 n
COR
wherein R is hydroxy, lower alkoxy or NH2;
R^ and R4 each is hydrogen, lower 20 alkyl or phenyl-lower alkyl;
R£ is hydrogen or R^-CO;
R^ is hydrogen, hydroxy or lower alkyl; R^ is lower alkyl, phenyl or phenyl-lower alkyl; and 25 n is 0, 1 or 2.
with an effective amount of a diuretic compound and such a combination of medicaments.
ttSed ksreiA "tower alKijl <X/\A " Iow<rr cxlfaxy shall ftVcluole caIu ty\oi'e'ties u>c"fiv -p'c/vi I ~hv Ur Ccx^Iooa Tcvyn
" lower adK&AOij( /acLucLo. U>cft\
2. i" & S' caytoA eLfevyv£
I* .
KO'*°
18 915 9
■IIA100;
The compounds of formula I have been reported to be angiotensin converting enzyme inhibitors which intervene in the angiotensinogen -*■ renin -* 5 angiotensin I -*■ angiotensin II mechanisn and are effective in reducing or alleviating hypertension. See U.S. Patent 4,046,889, September 6, 1977;
Science 196, 441-443 (1977). It has been found that such compounds can be used in an oral dosage range 10 °f about 0.1 to 100 mg/kg per day and are most effective when provided at a total daily dosage of about 60 to 600 mg. Dosages within this range achieve a substantial reduction in arterial blood pressure and, in most instances, little, if any significant 15 reduction is obtained by further increasing the dosage. Although certain peptides, teprotide (SQ20,881) for example, have been reported to have angiotensin converting enzyme activity, they are not of practical use for such an indication because of the cost 20 particularly since they are ineffective when orally administered fRubin et al., 204, Jour. Pharm. Exper. Ther. 271-280, 1978; Laffan et al., Jour.
Pharm. Exper. Ther. 204, 281-288, 1978; Brit. Med.
Jour. 2 (6141); 866, 1978].
Hypertension is also frequently treated by the administration of a diuretic. Typically, treatment with an antihypertensive agent alone results in a compensatory retention of sodium and water which concomitant administration of a diuretic 3Q prevents (Wollam et al., Drugs 14^420-460, 1977).
However, administration of a compound of formula I does not result in sodium and water
189159
-Hft±-6TJa~
retention when administered alone and, in fact, may by itself cause natriuresis and diuresis (Bengis et al, Circulation Research, Vol. 4_3 1-45-1-53, 1978). Therefore, a diuretic would not be expected to enhance the antihypertensive action of compounds of formula I. However, it has been demonstrated that the administration of a diuretic in combination with compounds of formula I is more effective than either drug alone. The combination of such compounds with a diuretic as described below results in a potentiation of the reduction in blood pressure significantly beyond-that level which either substance can achieve itself at a dosage within the acceptable range and also at lower dosage levels.
This invention therefore relates to a combination of a compound having formula I above and a diuretic of the group consisting of the thiazide class, e.g., chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methychlo-thiazide, trichlormethiazide, polythiazide or benzthiazide, as well as ethacrynic acid, ticrynafen, chlorthalidone, furosemide, bumetanide, triamterene, amiloride and spironolactone, and salts of such compounds, compositions comprising a combination of 22 such compounds and to a method for alleviating hyper tension with a combination of compounds.
Preferred are those compounds of formula I wherein R is hydroxy or lower alkoxy, especially C^-C^ lower alkoxy; R^ is hydrogen or lower alkyl, especially methyl, R2 is hydrogen or lower alkanoyl, especially C2-C4 i°wer alkanoyl; R^ is hydrogen
18915 9
or hydroxy, especially 4-hydroxy; is hydrogen or lower alkyl, especially c^~cq lower alkyl; and n is 0 or 1. Especially preferred in this group are compounds of formula I wherein R is hydroxy; R^ is 5 hydrogen or methyl; R2 is hydrogen or acetyl; R^ is hydrogen; R^ is hydrogen or methyl; and n is 0 or 1. The especially preferred embodiment includes a compound of formula I wherein R is hydroxy; R^ is methyl; R^, R^ and R^ each is hydrogen; and n is 1, 10 most especially (D-3-mercapto-2-methylpropanoyl)-L-
proline.
Preferred as the second component of the combination is chlorothiazide, hydrochlorothiazide, furosemide, ticrynafen or triamterene, especially 15 hydrochlorothiazide or furosemide.
The especially preferred embodiments are compositions comprising (D-3-mercapto-2-methyl-propanoyl)-L-proline with either hydrochlorothiazide or furosemide.
The compounds of formula I can be produced as described in U.S. Patent 4,046,889, September 6, 1977. The diuretic members of the combination are known compounds which are produced by methods described in the literature.
According to this invention, a combination of a compound of formula I and a diuretic is administered in an effective amount which comprises a total daily dosage of about 30 to 600 mg., preferably 30 to 300 mg. of a compound of formula I and about 3Q 15 to 300 mg. preferably 15 to 200 mg. of the diuretic to a mammalian species which has elevated blood
*
18915 9
#&L£Jlar~
pressure. Such total daily dosages can be used in a single administration of the total amount or in divided doses two to four times daily. Generally, a t.i.d. or q.i.d. regimen is preferred. This preferred dosage is about 10 to 100 mg. of the compound of formula I and about 5 to 75 mg. of the diuretic three times daily or about 5 to 125 mg. of the compound of formula I and about 2.5 to 50 mg. of the diuretic four times daily. The preferred route of administration is oral.
According to one preferred embodiment, the substances can be formulated in a single pharmaceutical dosage form for oral administration such as tablet, capsule, solution or suspension comprising an effective amount of each of the active ingredients in a physiologically acceptable carrier therefor.
The active substances in the dosage unit are present in a ratio of about 1:2 to about 12:1,
preferably about 2.5:1 to about 10:1, of the compound of formula I with respect to the diuretic (by weight). Generally, about 10 to 200 mg. of a compound of formula I and about 2.5 to 100 mg. of the second component can be readily formulated in the composition.
Tablets of various sizes can be prepared, e.g., of about 50 to 700 mg. in total weight, containing the active substances in the ranges described above,
with the remainder being a physiologically acceptable carrier or other materials according to accepted pharmaceutical practice. These tablets can, of course, be scored to provide for fractional doses. Gelatin capsules can be similarly formulated.
1891
«Al60a.
Liquid formulations can also be prepared by dissolving or suspending the combination of active substances in a conventional liquid vehicle acceptable for pharmaceutical administration so as to provide the desired dosage in one to four teaspoonsful.
Such dosage forms can be administered to the patient on a regimen of one to four doses per day.
According to another modification, in order to more finely regulate the dosage schedule, the substances may be administered separately in individual dosage units at the same time or carefully coordinated times. Since blood levels are built up and maintained by a regulated schedule of administration, the same result is achieved by the simultaneous presence of the two substances. The respective substances can be individually formulated in separate unit dosage forms in a manner similar to that described above.
Fixed combinations of the compound of formula I and the diuretic are more convenient and are preferred, expecially in tablet or capsule form for oral administration.
In formulating the compositions of this invention the active substances, in the amounts described above, are compounded according to accepted pharmaceutical practice with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavor, etc., in the particular type of unit dosage form.
Illustrative of the adjuvants which may be incorporated in tablets are the following: a binder such as gum tragacanth, acacia, corn starch or gelatin;
189159
hai fin*- %
an excipient such as dicalcium phosphate or cellulose; a disintegrating agent such as corn starch, potato starch, alginic acid or the like; a lubricant such as stearic acid or magnesium stearate; a sweetening agent such as sucrose, lactose or saccharin; a flavoring agent such as orange, peppermint, oil of wintergreen or cherry. When the dosage unit form is, a capsule, it may contain in addition to materials of the above type a liquid carrier such as a fatty oil. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, water, alcohol or the like as the carrier, glycerol as solubilizer, sucrose as sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange.
Many of the active substances described above form commonly known, pharmaceutically acceptable salts such as alkali metal and other common basic salts or acid addition salts, etc. References to the base substances are therefore intended to include those common salts known to be substantially equivalent to the parent compound.
The following examples are illustrative of the invention and constitute especially preferred embodiments. They also serve as models for the preparation of other members of the group which can be produced by suitable substitution of ingredients as described above.
189159
i
^HA160q
-8-Example 1
6000 tablets each containing the following ingredients:
(D-3-mercapto-2-methylpropanoyl)-5 L-proline 100 mg.
Avicel (microcrystalline cellulose) 100 mg.
Hydrochlorothiazide 12.5 mg.
Lactose U.S.P. 113 mg.
Corn starch U.S.P. 17.5 mg.
Stearic acid U.S.P. 7 mg.
350 mg.
are produced (from sufficient bulk quantities) by slugging the (D-3-mercapto-2-methylpropanoyl)-L-proline, Avicel and a portion of the stearic acid. 15 The slugs are ground and passed through a #2 screen,
then mixed with the hydrochlorothiazide, lactose, corn starch and remainder of the stearic acid. The mixture is compressed into 350 mg. capsule shaped tablets in a tablet press. The tablets are scored 20 for dividing in half.
Example 2
,000 tablets each containing the following ingredients:
(D-3-mercapto-2-methylpropanoyl)-25 L-proline 200 mg.
Corn starch U.S.P. 17.5 mg.
Lactose U.S.P. 215.4 mg.
Acacia U.S.P. 10.6 mg.
Water qs (ca. 0.03 ml.)
Hydrochlorothiazide 25 mg.
Corn starch U.S.P. 17.5 mg.
18915 9
-HAl6fta
Avicel 200 mg.
Stearic Acid 14 mg.
700 mg.
are produced from sufficient bulk quantities as 5 follows:
The acacia is dissolved in water. 17.5 mg. of corn starch, the (D-3-mercapto-2-methylpropanoyl)-L-proline and lactose are mixed thoroughly. The dry mixture is granulated using the aqueous solution of 10 acacia. The granulation is wet screened, dried at
120°F. and reduced. The reduced, dry granulation is mixed with the hydrochlorothiazide and the remaining excipients are then added and mixed. The mixture is compressed into tablets of 700 mg. each. 15 Example 3
Tablets each containing the following ingredients are made as described in Example 2:
(D-3-mercapto-2-methylpropanoyl)-
L-proline
75
mg.
Corn starch U.S.P.
8
mg.
Lactose U.S.P.
120
mg.
Acacia U.S.P.
6
mg.
Water qs.
(ca. 0.
03 ml.)
Chlorothiazide
50
mg.
Corn starch U.S.P.
8
mg.
Avicel
75
mg.
Stearic acid
8
mg.
350
mg.
Example 4
1000 capsules, each containing the following ingredients:
18915 9
' -ilAlGOa
(D-3-mercapto-2-methylpropanoyl)-
L-proline 100 mg.
Lactose U.S.P. 211.8 mg.
Magnesium stearate 3.2 mg.
Hydrochlorothiazide 10 mg.
325 mg.
are produced by dry blending the bulk materials (except the magnesium stearate) in a Hobart mixer,
then passing the blend through a #20 screen. The 10 materials are mixed again in the Hobart mixer with the magnesium stearate. The mixture is then filled into #2 two-piece gelatin capsules.
Example 5
By substituting 10 mg. of furosemide for the 15 hydrochlorothiazide in Example 4, capsules containing furosemide and (D-3-mercapto-2-methylpropanoyl)-L-proline are similarly produced.
Example 6
By following the proceudre of Example 2 but 20 substituting 20 mg. of furosemide for the hydrochloro thiazide and using 220.4 mg. of lactose, 700 mg. tablets each containing 20 mg. of furosemide and 200 mg. of (D-3-mercapto-2-methylpropanoyl)-L-proline are similarly produced. 25 Example 7
By substituting 10 mg. of furosemide for the hydrochlorothiazide and using 115.5 mg. of lactose in the procedure of Example 1, 350 mg. scored tablets each containing 10 mg. of furosemide and 30 100 mg. of (D-3-mercapto-2-methylpropanoyl)-L-
proline are similarly produced.
1891
-ttftfbUa
Example 8
6000 scored tablets of 400 mg. each and containing the following ingredients:
(D-3-mercapto-2-methylpropanoyl)-
L-proline
125
mg.
Corn starch
8
mg.
Lactose U.S.P.
95
mg.
Acacia
7
mg.
Water qs.
(ca. 0.03
ml.)
Triamterene
50
mg.
Corn starch U.S.P.
8
mg.
Avicel
100
mg.
Stearic acid
7
mg.
400
mg.
are produced as described in Example 2.
Example 9
6000 scored tablets of 350 mg. each and containing the following ingredients:
(D-3-mercapto-2-methylpropanoyl)-L-proline 100 mg.
Avicel 100 mg.
Triamterene 25 mg.
Lactose U.S.P. 100 mg.
Corn starch U.S.P. 17 mg.
Stearic acid 8 mg.
350 mg.
are produced as described in Example 1.
Example 10 5000 scored tablets of 180 mg. each and containing the following ingredients: (D-3-mercapto-2-methylpropanoyl)-L-proline 10 mg.
1891
HAlliUd' '
Avicel
50 mg.
Hydrochlorothiazide Lactose U.S.P.
Corn starch U.S.P. Stearic acid
mg.
101 mg.
mg.
4 mg.
180 mg.
are produced as described in Example 1. Example 11
By substituting the same amount of ticrynafen for the hydrochlorothiazide in Example 1, tablets containing 10^ mg. of (D-3-mercapto-2-methylpropanoyl)-L-proline and 12.5 mg. of ticrynafen are similarly obtained.
Representative of the results obtained with combinations of agents of this invention are data obtained from studies in spontaneously hypertensive rats and two kidney renal hypertensive rats.
A) In an acute study with spontaneously hypertensive rats, ten to fourteen week old male Wistar-Kyoto spontaneously hypertensive rats (190-210 gm.) of the Okamoto-Aoki strain (obtained from Taconic Farms, Germantown, N.Y.) were given food and water ad libitum and intubated according to the method of Weeks and Jones, Proc. Soc. Exp.
Biol. Med. 104, 646-648 (1960), to prepare them for blood pressure and heart rate determination by implanting indwelling abdominal aortic catheters under sodium pentobarbital anesthesia.
Three weeks later their direct blood pressure and heart rate were recorded by the method of Laffan et al., Cardiovasc. Res. 6, 319-324 (1972), modified
189159
-HA160a—
as follows. The signal from the transducer was digitized in a 10 bit A/D converter and input to a PDP 11/05 computer. The computer was programmed to sense and store samples at a rate of 125/sec for each rat, as well as the number of pressure pulses during 10 sec. of each scan on each rat. These parameters were averaged and stored as the MBP (mean blood pressure, mm Hg) and heart rate (beats/min.) for that time. Data were acquired from each rat every five minutes. Six such sets of data were averaged to give a mean •"■alue representing a 30 minute sample and this 30 minute figure was stored for subsequent analysis. Each time a 48 hour cycle was completed (or sooner if demanded) the data were 25 transferred serially to a host computer (PDP 11/40)
for further analysis and the data were printed out on a Versatec Printer/Plotter for at least 16 hours after each dose.
The spontaneously hypertensive rats were segregated 2q into four groups of five rats each (except group 3
which included six rats). The following was administered to the rats in the respective groups:
1. (Control) Agar - 5 ml./kg + agar - 5 ml./kg
★
2. Water - 5 ml./kg + Compound A - 30 mg./kg
* *
9_ 3. Compound F - 50 mg./kg + Agar - 5 ml./kg
★ ★ ic
4. Compound F - 50 mg./kg + Compound A 30 mg./kg
* Compound A = (D-3-mercapto-2-methylpropanoyl)-
L-proline ** Compound F = Furosemide
18 915 9
«fi£ri^Ua 3
Compound F was suspended in 0.25% agar and Compound A was in aqueous solution. All substances were administered by gavage and there was a one hour interval between drugs. Test results were evaluated 2.5 hours after single oral doses.
The following results were obtained:
TABLE I
Mean Blood Pressure (mm/Hg)
Before 2.5 hours after single oral dose
(1) 173 169
(2) 175 158
(3) 184 172
(4) 177 128
In these studies Compound F alone, 50 mg./kg. p.o., produced a 9.7% decrease in SHR blood pressure. Compound A alone, 30 mg./kg., produced 6.5% decrease in blood pressure. The combination of Compound A, 30 mg./kg., p.o., + Compound B, 50 mg./kg., p.o.,
reduced blood pressure in SHR rats by 27.7%.
B) In chronic studies with renal hypertensive rats, male rats (115-150 g.) of the Charles River Sprague Dawley (COBS-CO) strain were anesthetized with ether and a silver clip (0.22 mm i.d.) was placed on the left renal artery through a flank incision. The contralateral kidney was left intact (two-kidney Goldblatt model: 2-K RHR). Each rat was fitted with a tail cuff for air inflation and a Korotkoff sound microphone for the detection of arterial pulsation. An oscilloscope was used for a visual appearance and disappearance of the pulse. Blood pressure measurements
i
189159
' -ilAlCOa ■
were determined after a minimum of six inflations with systolic pressures observed on a Narco physiograph manometer. Blood pressures were determined initially just prior to dosing and twice weekly at 4 hours after 5 dosing.
The number of rats in each group was 15. Single daily treatments were made by gavage with crossover treatments as indicated in the table below. The control group received distilled water. Compound A 10 was administered in distilled water, 30 mg./kg.
Compound H war administered in 0.25% methylcellulose. The mean blood pressure (mm/Hg.) for each group before dosing and on day 119 (4 hours after dosing) and the number of survivors on day 120 is shown 15 in the table.
u> i_n
OJ
o
NJ
Ln to o
U1
tn
TABLE II
Group
1
2
3
4
6
7
Treatment h2°
H2° H2°
A A A H
Crossover^ Treatment
H2°
H20 + A H20 + H
y #
A + H H
Mean
No.
of
Blood Pressure
Survivors
Initial
Day 119
198-4.9
207-6.
6
(66.7)
198-4.9
206-5.
2
(66.7)
206-7.5
207-4
8
11
(73.3)
197-5.3
167-4.
6
14
(93.3)
197-6.2
176-5.
1
14
(93.3)
202-6.6
140-4.
6
(100)
197-5.8
202^8.
4
8
(53.3)
* Crossover took place on day 28 through day 33 and on day 91 through day 96 (except Group 6 - see below).
# Daily dosage of each maintained from day 109 on. A = (D-3-mercapto-2-methylpropanoyl)-L-proline
H = Hydrochlorothiazide
<n I
c
< 5
I
189159
The foregoing data show that on long term treatment compound H shows no significant decrease in blood pressure. Compound A alone shows approximately a 10 to 15% reduction in blood pressure. The combination dosing with Compound A and Compound H shows approximately a 30% reduction in blood pressure. Moreover, the combination is the only one showing a 100% survivor rate.
18
Claims (16)
1. An oral dosage unit having a synergistic anti-hypertensive effect comprising 30 to 600 mg of a compound of the formula wherein R is hydroxy, lower alkoxy having from 1 to 4 carbon atoms or NH2: Rl and R4 each is hydrogen, lower alkyl having from 1 to 4 carbon atoms or phenyl-lower alkyl wherein the lower alkyl moiety has from 1 to 4 carbon atoms; R.2 is hydrogen or R5-CO; R3 is hydrogen, hydroxy or lower alkyl having from 1 to 4 carbon atoms; R5 is lower alkyl having from 1 to 4 carbon atoms, phenyl or phenyl-lower alkyl where the lower alkyl moiety has from 1 to 4 carbon atoms; and n is 0, 1 or 2, and 15 to 300.mg of a diuretic selected from chlorothiazide, hydrochlorothiazide, amiloride, flumethiazide, hydroflumethiazide, bendroflu-methiazide, methycl©thiazide, trichlormethiazide, polythiazide, benzthiazide, ethacrynic acid, tricrynafen, chlorthalidone, furose- e R R - 19 - mide, bumetanide, triamterene, spironolactone and salts thereof.
2. A dosage unit as in claim 1 comprising 30 to 300 mg of the com-
3. A dosage unitasin claim 1 wherein the compound of the formula has R as hydroxy or lower alkoxy having from 1 to 4 carbon atoms; Ri as hydrogen or lower alkyl having from 1 to 4 carbon atoms; R2 as hydrogen or lower alkanoyl having from 2 to 5 carbon atoms; R3 as hydrogen or hydroxy; R4 as hydrogen or lower alkyl having from 1 to 4 carbon atoms; and n as 0 or 1.
4. A dosage unit as in claim 1 wherein the compound of the formula has R as hydroxy; Ri as hydrogen or methyl; R2 as hydrogen or acetyl; R3 as hydrogen; R4 as hydrogen or methyl; and n as 0 or 1.
5. A dosage unit as in claim 1 wherein the diuretic is chlorothiazide, hydrochlorothiazide, furosemide, ticrynafen or triamterene.
6. A dosage unit as in claim 1 wherein the diuretic is hydrochlorothiazide or furosemide.
7. A dosage unit as in claim 1 wherein the compound of the formula has R as hydroxy or lower alkoxy having from 1 to 4 carbon atoms; Ri as hydrogen or lower alkyl having from 1 to 4 carbon atoms; R2 as hydrogen or lower alkanoyl having from 2 to 5 carbon atoms; R3 as hydrogen or hydroxy; R4 as hydrogen or lower alkyl having from 1 to 4 carbon atoms; and n as 0 or 1; and the diuretic is chlorothiazide, hydrochlorothiazide, furosemide, ticrynafen or triamterene. pound of the formula and 15 to'^OO.mg of the diuretic. - 20 -
8. A dosage unit as in claim 1 wherein the compound of the formula is (D-3-mercapto-2-methylpropanoyl)-L-proline and the diuretic is hydrochlorothiazide or furosemide.
9. A dosage unit as in claim 1 comprising 30 to 300 mg of (D-3-mercapto-2-methyIpropanoyl)-L-proline and 15 to 200 mg of hydrochlorothiazide.
10. A dosage unit as in claim 1 comprising 30 to 300 mg of (D-3-mercapto-2-methylpropanoyl)-L-proline and 15 to 200 mg of furosemide.
11. A dosage unit as in claim 1 comprising 5 to 125 mg of (D-3-mercapto-2-methyIpropanoyl)-L-proline and 2.5 to 50mg of hydrochlorothiazide.
12. A dosage unit as in claim 1 comprising 5 to 125 mg of (D-3-mercapto-2-methylpropanoyl)-L-proline and 2.5 to 50 mg of furosemide.
13. A dosage unit as in claim 1 comprising 5 to 125 mg of (D-3-mercapto-2-methylpropanoyl)-L-proline and 5 to 75 mg of triamterene.
14. A dosage unit as claimed in any one of the preceding claims wherein said compound of the formula as defined in claim 1 and the diuretic selected from the group defined in claim 1 are in the form of a composition.
15. A dosage unit as claimed in claim 14 wherein said composition includes a physiologically acceptable carrier.
16. A dosage unit as claimed in any one of the preceding claims substantially as hereinbefore described with reference to any of the Examples. , 12JULI984
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86442877A | 1977-12-27 | 1977-12-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ189159A true NZ189159A (en) | 1984-12-14 |
Family
ID=25343256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ189159A NZ189159A (en) | 1977-12-27 | 1978-12-13 | Oral antihypertensive compositions containing proline derivatives |
Country Status (30)
| Country | Link |
|---|---|
| JP (1) | JPS54110333A (en) |
| AR (1) | AR230378A1 (en) |
| AU (1) | AU526239B2 (en) |
| BE (1) | BE873092A (en) |
| CA (1) | CA1120400A (en) |
| CH (1) | CH642542A5 (en) |
| DE (1) | DE2854316C3 (en) |
| DK (1) | DK578778A (en) |
| EG (1) | EG14178A (en) |
| FI (1) | FI783991A (en) |
| FR (1) | FR2413089A1 (en) |
| GB (1) | GB2010675B (en) |
| GR (1) | GR72951B (en) |
| HK (1) | HK45483A (en) |
| HU (1) | HU178747B (en) |
| IE (1) | IE48306B1 (en) |
| IL (1) | IL56281A (en) |
| IT (1) | IT1202811B (en) |
| KE (1) | KE3235A (en) |
| LU (1) | LU80709A1 (en) |
| MY (2) | MY8300240A (en) |
| NL (2) | NL192870C (en) |
| NO (1) | NO784357L (en) |
| NZ (1) | NZ189159A (en) |
| PH (1) | PH22111A (en) |
| PL (1) | PL212188A1 (en) |
| PT (1) | PT68983A (en) |
| SE (1) | SE445173B (en) |
| SG (1) | SG41482G (en) |
| ZA (1) | ZA786948B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5829950B2 (en) * | 1978-10-05 | 1983-06-25 | ウェルファイド株式会社 | Cyclic iminocarboxylic acid derivatives and their salts |
| US4350704A (en) | 1980-10-06 | 1982-09-21 | Warner-Lambert Company | Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids |
| US4482725A (en) * | 1980-04-03 | 1984-11-13 | E. R. Squibb & Sons, Inc. | S-Acylation products of mercaptoacyl amino acids and carboxyl group containing diuretics |
| US4344949A (en) | 1980-10-03 | 1982-08-17 | Warner-Lambert Company | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
| US4532342A (en) * | 1981-02-20 | 1985-07-30 | Warner-Lambert Company | N-substituted amino acids as intermediates in the preparation of acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
| US4552889A (en) * | 1983-06-09 | 1985-11-12 | Eli Lilly And Company | 3-Mercaptomethyl-2-oxo-1-pyrrolidine acetic acids and use for hypertension |
| US4898729A (en) * | 1983-12-09 | 1990-02-06 | Euroceltique, S.A. | Treatment of hypertension, compounds and compositions for antihypertension and diuresis |
| DE3532036A1 (en) * | 1985-09-09 | 1987-03-26 | Hoechst Ag | PHARMACEUTICAL PREPARATION FOR TREATING HIGH PRESSURE |
| DK9200258U4 (en) * | 1992-03-11 | 1993-07-23 | Merck & Co Inc | Pharmaceutical preparation containing enalapril for use in hypertension |
| WO1996024358A1 (en) * | 1995-02-10 | 1996-08-15 | G.D. Searle & Co. | Use of low dose amount of spironolactone for treatment of cardiovascular disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU509899B2 (en) * | 1976-02-13 | 1980-05-29 | E.R. Squibb & Sons, Inc. | Proline derivatives and related compounds |
-
1978
- 1978-11-21 CA CA000316609A patent/CA1120400A/en not_active Expired
- 1978-11-29 AU AU42041/78A patent/AU526239B2/en not_active Expired
- 1978-12-06 IE IE2413/78A patent/IE48306B1/en unknown
- 1978-12-06 FR FR7834359A patent/FR2413089A1/en active Granted
- 1978-12-12 ZA ZA786948A patent/ZA786948B/en unknown
- 1978-12-13 NZ NZ189159A patent/NZ189159A/en unknown
- 1978-12-14 NL NL7812164A patent/NL192870C/en not_active IP Right Cessation
- 1978-12-14 GR GR57879A patent/GR72951B/el unknown
- 1978-12-14 CH CH1273778A patent/CH642542A5/en not_active IP Right Cessation
- 1978-12-15 DE DE2854316A patent/DE2854316C3/en not_active Expired - Lifetime
- 1978-12-19 PH PH21971A patent/PH22111A/en unknown
- 1978-12-21 GB GB7849703A patent/GB2010675B/en not_active Expired
- 1978-12-22 SE SE7813277A patent/SE445173B/en not_active IP Right Cessation
- 1978-12-22 NO NO784357A patent/NO784357L/en unknown
- 1978-12-22 HU HU78SU1000A patent/HU178747B/en unknown
- 1978-12-22 LU LU80709A patent/LU80709A1/en unknown
- 1978-12-22 IL IL56281A patent/IL56281A/en unknown
- 1978-12-22 DK DK578778A patent/DK578778A/en not_active Application Discontinuation
- 1978-12-22 IT IT31266/78A patent/IT1202811B/en active Protection Beyond IP Right Term
- 1978-12-25 EG EG740/78A patent/EG14178A/en active
- 1978-12-25 JP JP16462778A patent/JPS54110333A/en active Granted
- 1978-12-26 PT PT68983A patent/PT68983A/en unknown
- 1978-12-27 PL PL21218878A patent/PL212188A1/xx unknown
- 1978-12-27 FI FI783991A patent/FI783991A/en unknown
- 1978-12-27 BE BE192574A patent/BE873092A/en not_active IP Right Cessation
- 1978-12-27 AR AR274975A patent/AR230378A1/en active
-
1982
- 1982-09-02 SG SG414/82A patent/SG41482G/en unknown
- 1982-09-14 KE KE3235A patent/KE3235A/en unknown
-
1983
- 1983-10-20 HK HK454/83A patent/HK45483A/en not_active IP Right Cessation
- 1983-12-30 MY MY240/83A patent/MY8300240A/en unknown
-
1987
- 1987-10-31 MY MYPI87003001A patent/MY102991A/en unknown
-
1998
- 1998-04-24 NL NL980017C patent/NL980017I1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4217347A (en) | Method of treating hypertension and medicaments therefor | |
| NZ189159A (en) | Oral antihypertensive compositions containing proline derivatives | |
| EP0629400B1 (en) | Idebenone compositions for treating Alzheimer's disease | |
| KR0178762B1 (en) | New medical use for a certain indole derivative and pharmaceutical composition containing it | |
| US5011841A (en) | Treatment of depression | |
| RU2298411C2 (en) | Using ginkgo biloba extracts in preparing medicinal agent designated for sarcopenia treatment | |
| DK165966B (en) | IMPROVED PIROXICAM CONTAINING ANTI-INFLAMMATORY PREPARATION | |
| US3988461A (en) | Pharmaceutical composition for the treatment of Parkinson's disease | |
| JPH0352816A (en) | Remedy for nephritis | |
| US3360434A (en) | Method for reducing blood pressure with phenylalanine derivatives | |
| JPH05504550A (en) | Pyrimidine biosynthesis inhibitor useful as an immunosuppressant | |
| GB1584089A (en) | Antihypertensive pharmaceutical compositions | |
| JPH0446124A (en) | Antiulcer agent | |
| US4061756A (en) | Methods for treating cardiovascular disorders | |
| SA90100151B1 (en) | A combination low-dose benazepril/thiazide diuretic | |
| US3904758A (en) | Method of increasing wakefulness | |
| IE53331B1 (en) | Amidinourea compositions for use in a method for relieving the discomfort of a human female attendant to menstruation | |
| EA003671B1 (en) | Riluzole and alpha-tocopherol combination | |
| JPH04279524A (en) | Therapeutic agent for cerebral blood vessel disease | |
| JP2545321B2 (en) | Smooth muscle contraction inhibitor | |
| JPH09500648A (en) | A method for inhibiting human immunodeficiency virus replication by substituted azaspirans. | |
| US4156003A (en) | Treatment of hypertension with combination of clofibrinic acid or clofibrate with cinnarizine | |
| US4089970A (en) | Method of inhibiting platelet aggregation | |
| JPH09500646A (en) | Treatment of HIV with azaspiran | |
| IE43955B1 (en) | Pharmaceutical composition and dosage units thereof |